Company Snapshot Home > Equity > Corporate Information > Company Snapshot
|
|
| Stock Price Details |
|
Chart |
|
|
Last Price (RS)
|
252.15
|
|
Change (%)
|
2.50 (1.00%)
|
|
Best Buy (RS)
|
0(x0)
|
|
Best Sell (RS)
|
0(x0)
|
|
Today's Range (RS)
|
248.40
-
259.95
|
|
52-Week Range (RS)
|
156.00
-
270.10
|
|
Beta (1 Year)
|
1.06
|
|
|
|
|
|
| Index Details |
| BSE HC, BSE SmallCap |
| News |
|
Corporate Details |
| Marksans Pharma receives revision in ratings outlook for bank facilities |
| Marksans Pharma to acquire Netherlands-based QliniQ B.V. |
| Indices witness profit booking; PSU Bank shares snap 5-day rally |
| Board of Marksans Pharma recommends final dividend |
| Marksans Pharma consolidated net profit rises 63.59% in the March 2026 quarter |
| Marksans Pharma soars after Q4 PAT jumps 64% YoY |
| Marksans Pharma grants 3 lakh stock options under ESOS |
| Marksans Pharma to convene board meeting |
| Marksans Pharma gains after Q3 PAT rises 8% YoY to Rs 113 crore |
| Marksans Pharma consolidated net profit rises 8.26% in the December 2025 quarter |
|
|
|
| Incoporation Year : 1992 |
| Chairman : Mark Saldanha |
| Ownership Group : Indian Private |
| Sector : MAN |
| Industry : Pharmaceuticals - Indian - Formulations |
| Registered Office |
Marksans Pharma Ltd
11th Flr GRANDEUR Oshiwara,
Veera Desai Extn Rd Andheri(W),
Mumbai,
Maharashtra-400053 |
Phone:91-22-40012000
Fax:91-22-40012011 |
| E-Mail : companysecretary@marksanspharma.com ; info@marksan |
| URL : http://www.marksanspharma.com |
|
| Investor Returns |
|
| |
Date |
Price |
Returns (%) |
| 1Week |
05-Jun-2026 |
233.00 |
8.22 |
| 1Month |
12-May-2026 |
198.60 |
26.96 |
| 3Month |
12-Mar-2026 |
173.30 |
45.50 |
| 6Month |
12-Dec-2025 |
193.95 |
30.01 |
| 1Year |
12-Jun-2025 |
260.60 |
-3.24 |
|
|
|
|
| Mutual Funds Holding |
|
| Scheme Name |
% Holding |
Market Value (Rs Cr.) |
| Bandhan Small Cap Fund |
0.32 |
86.79 |
| UTI-Small Cap Fund |
1.59 |
78.93 |
| Kotak Special Opportunites Fund |
4.45 |
63.46 |
| UTI-Aggressive Hybrid Fund |
0.84 |
54.60 |
| UTI-Large & Mid Cap Fund |
0.87 |
51.85 |
|
|
|
|
| Groups : Pharmaceuticals - Indian - Formulations |
|
| Company |
Last Price |
Change (%) |
52Week High |
52Week Low |
Market Cap (Rs Cr.) |
| Torrent Pharmaceuticals Ltd |
4,574.95 |
0.11 |
4,714.50 |
3,139.50 |
154,837.10 |
| Ajanta Pharma Ltd |
3,129.35 |
-0.34 |
3,314.80 |
2,335.00 |
39,096.73 |
| Gland Pharma Ltd |
2,261.10 |
-1.93 |
2,395.00 |
1,575.00 |
37,299.03 |
| Rubicon Research Ltd |
1,294.35 |
0.52 |
1,371.75 |
571.00 |
21,324.46 |
| ERIS Lifesciences Ltd |
1,402.90 |
2.64 |
1,909.55 |
1,237.90 |
19,439.60 |
|
|
|
|